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Hairy cell leukemiaHairy cell leukemia was initially described as a clinicopathologic entity more than 50 years ago. We have
subsequently discovered that HCL is really at least two diseases: classical HCL and the hairy cell leukemia variant.
The former is among a small group of cancers exceptional for being (nearly) uniﬁed by a single genetic lesion, the
BRAF V600E mutation. Over the past three decades, tremendous progress in both diagnostic and prognostic
clariﬁcation has been accompanied by therapeutic advances in classical HCL. Consequently, this once uniformly
fatal disease has been converted in most cases into a chronic illness enabling patients to live long and productive
lives. In response to standard therapy, patients have high complete remission rates. Unfortunately, the long-term sur-
vival curves have not plateaued, revealing that this disease is controlled but not cured. Though rare and representing
only about 10%of analready raredisease, thosepatientswith the variant fare exceptionallypoorlywith standard ther-
apy: complete response rates to purine nucleoside analogs are reported to be less than 50%, whereas the complete
response rates in classical HCL are up to 90%. Novel small molecules targeting BRAF and the B-cell receptor signaling
complex, and biologic agents like antibodies and immunotoxin conjugates are being explored for those patients who
have relapsed. Substantial opportunities for continued research remain. This complex and multi-faceted disease in-
corporates challenges from altered immunity associatedwith the underlying disease and its treatments. Considering
the rarity of this malignancy, optimization of patient management requires multi-institutional collaboration. The
Hairy Cell Leukemia Foundation (www.hairycellleukemia.org) was formed to coordinate these efforts.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hairy cell leukemia (HCL) was initially recognized as a distinct
clinical and pathologic entity by Bouroncle and colleagues in 1958 [1].
Initially called leukemic reticuloendotheleosis, this rare chronic
leukemia features a distinctivemalignant cell characterized by a spongy
appearance of the nucleus and a blue cytoplasm with an irregular,
serrated border. While the cell of origin of this leukemia has been
ascribed to a mature monoclonal B cell based upon the expression of
CD19, surface immunoglobulin, and clonal rearrangements of immuno-
globulin genes, recent studies suggest that the pathogenesis of this
disorder involves mutations in the hematopoietic stem cells [2]. HCL is
a rare leukemia, comprising only 2% of all leukemias and approximately
8% of all lymphoproliferative disorders, with an estimated 900 new92, Columbus, OH 43210, USA.
ever),
osumc.edu (L.A. Andritsos).
. This is an open access article undercases diagnosed each year in the United States according to SEER data.
The epidemiology remains only partially elucidated, with occupations
involving exposure to diesel fuel, organic solvents, large animal farming,
and pesticide and herbicide exposure being implicated in the develop-
ment of the disease [3]. No effect of ionizing radiation was identiﬁed.
In the U.S., the development of HCL in patients with prior military
exposure to Agent Orange, an herbicide used during the VietnamWar,
is now considered a service related illness according to the Institute of
Medicine's Veterans and Agent Orange: Update 2012 published by The
National Academies Press in 2014. The most frequently presented com-
plaints are weakness and fatigue, with infection being a feature in ap-
proximately 17% of the patients [4]. In addition to infectious
complications, the clinical course of the disease is principally associated
with consequences related to bone marrow failure and organomegaly.
Historically, splenomegaly was found in up to 96% of the patients [1],
however the frequency of marked splenomegaly may be less common
as the diagnosis is now being made earlier in the disease course than in
the past as a result of abnormalities uncovered on a routine blood count
[5,6]. The gender distribution of this leukemia remains unexplained,
with a 4:1 ratio of men to women. While patients may present at anythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Immunophenotypic markers can help distinguish hairy cell leukemia from other
lymphoid malignancies, and help differentiate the classical form from the variant.
Occasionally, differentiatingHCL, especially HCL variant or classicHCLwith slightly aberrant
immunophenotype (e.g., CD25 or CD103 negative), from splenicmarginal zone lymphoma
(SMZL) can be difﬁcult. Highlighted markers, incorporating a measure of brightness of
expression, showed good power to discriminate among the three diseases in a study by
Shao et al. [16] of 169, 35, and 9 cases of HCL, HCLv, and SMZL, respectively.
HCL HCL variant SMZL
Surface Ig +/− +/− +
CD5 − − −/+
CD10 − − −
CD11c +
(99%; 96% bright)
+
(100%; 63% bright)
−/+
(67% dim)
CD19 + + +
CD20 + + +
CD22 + + +
CD23 −/+ − -/+
CD25
(IL2R-α)
+
(100%; 98% bright)
−
(0%)
−
(22% dim)
CD37 + ? ?
CD103 +
(100%)
+
(100%)
−
(0%)
CD123
(IL3R)
+
(114/114, 100%)
−/+
(8/20, 40%)
−
(1/4, 25%)
198 M.R. Grever et al. / Blood Reviews 28 (2014) 197–203age throughout adult life, the median age at diagnosis is approximately
55 years old. At the time that this disease was ﬁrst described, the clinical
course was typically associated with a fatal outcome and an estimated
median survival of approximately six years, with substantial variability
[4]. Mortality was mostly attributable to infection or bleeding complica-
tions. Enormous progress has been made over the past two decades,
and the majority of patients with classic hairy cell leukemia may now
expect to live a near normal life span [7,8]. Although no curative therapy
currently exists, the disease can be controlled for long periods of time
with available therapy. Purine nucleoside analog (PNA) therapy induces
a high complete response (CR) rate both during initial therapy and as
re-induction therapy, however the greatly expanded life expectancy
that has been achieved with PNA therapy has created the need for
alternative therapies with novel mechanisms of action for the treatment
of patients with chemotherapy-resistant disease or treatment-associated
marrow damage [9–13]. Many questions remain unanswered and
deserve further clinical investigation to truly optimize the outcomes for
patients with this disease [7].
2. Immunophenotypic and molecular characterization of HCL
TheWHO now recognizes classic hairy cell leukemia (HCLc) and the
variant of hairy cell leukemia (HCLv) as two distinct clinical entities,
representing a major advancement in the further biologic characteriza-
tion of these diseases [14,15]. Although the variant accounts for only
about 10% of cases of hairy cell leukemia, its deﬁnition and clinical
recognition as a distinct entity are considerably important, as these
patients typically have more aggressive disease with worse response
to standard therapies [16]. This difference is dramatic: whereas up to
90% of patients with classical HCL may achieve a CR with PNA therapy
alone, fewer than 50% of variant patients do [17]. Recently, Kreitman
showed that cladribine combined with rituxan produced a high
complete response in HCLv but follow-up will be needed [17]. Correct
identiﬁcation of HCLv is important in light of these differential re-
sponses to therapy as well as for potential eligibility in clinical trials of
new agents. Patients with the classic form of this disease have a distinct
immunophenotypic proﬁle on their malignant leukemic cells: CD20+,
CD19+, CD11c+, CD25+, CD103+, and CD123+. In contrast, the leukemic
cells from patients with the variant form of hairy cell leukemia are
characterized as being CD11c+, CD20+, and CD19+; whereas CD25
and CD123 are typically negative (Table 1) [7,18,19]. Recently additional
molecular features that distinguish these different subsets of the disease
have been identiﬁed [20,21]. Patients with classic hairy cell leukemia
predominantly have cells that possess the BRAF p.V600E mutation,
with both diagnostic and therapeutic implications. Patients with the
variant HCL do not have this mutation, but show wild type BRAF. With
the introduction of BRAF inhibitors, and with the lower response rate
of HCLv to standard therapies, determination of BRAFmutation status is
therefore important in distinguishing these entities.While Tiacci initially
identiﬁed the speciﬁc BRAF V600E mutation by genome analysis with
Sanger sequencing, recently a mutation-speciﬁc antibody (VE1) has
been developed that can be used to recognize this mutation on
formalin-ﬁxed parafﬁn embedded tissue sections. This advancement is
important because immunohistochemistry is more readily available in
the majority of diagnostic laboratories than genomic sequence analysis,
and the VE1 antibody is reported to be more accurate in detecting
minimal residual disease [22,23]. Key differentiating features of classical
and variant HCL are listed brieﬂy in Table 2.
A number of recent studies have contributed additional potential
markers of inferior response to therapy and worse overall prognosis
[21,24–26]. Studies have suggested that patients with hairy cell leuke-
mia expressing an un-mutated immunoglobulin gene may resemble
un-mutated CLL in terms of worse prognosis and shortened survival.
Similarly, TP53 defects have been linked with decreased progression-
free survival after initial therapy with a purine analog. Recently,
Kreitman and colleagues found that patients with hairy cell leukemiaexpressing IGHV4-34 also have an inferior therapeutic response, indicat-
ing that this may be of importance in the risk stratiﬁcation analysis at
the time of diagnosis. In fact, although this subset of patients' leukemias
may resemble classic hairy cell leukemia immunophenotypically, BRAF
V600Emutation is usually absent, as it is in variant HCL [21]. Additional
investigation by whole-genome sequencing has further linked BRAFwt,
IGHV4-34+ classical HCL pathogenically to variant HCL through the
discovery of a high percentage of MAP2K1 mutations, suggesting a
critical role for the RAF–MEK–ERK signaling pathway in both classical
and variant HCL [26]. In many ways, the patients with these differing
features represent unique subsets of HCL and constitute molecular
variants of the disease. While the immunophenotypic proﬁle of the
leukemic cells has beenmost often utilized to establish the basic diagnosis,
molecular proﬁlingmay have a role in the identiﬁcation of patients who
are more likely to achieve durable remissions to standard therapy.
Consequently, if validated, the use of these reﬁned predictors of
response and molecular classiﬁcations may not only justify therapy
with novel approaches, but will also guide, which targeted therapy
may be most appropriate.
3. Clinical manifestations presenting opportunities for
continued research
3.1. Infection prophylaxis and treatment
Infectious complications have been a hallmark of the clinical
course of patients with hairy cell leukemia, and were the most
frequent cause of death before effective therapy [5,27]. Patients
may be signiﬁcantly immunocompromised as a result of the underlying
disease or following immunosuppressive chemotherapy. The propensi-
ty to bacterial and atypical opportunistic infections has been attributed
to the granulocytopenia and absolute monocytopenia observed in the
classic form of the disease, with disrupted mononuclear cell and lym-
phocyte function additionally underlying an immunocompromised
state [28–30]. Atypical infections with mycobacterial organisms reﬂect
difﬁculties in handling intracellular pathogens,while prolongedneutro-
penia may lead to an increased risk of invasive fungal infections [31].
Pneumocystis jirovecii pneumonia can result from immune deﬁcits
existing before therapy, and has also been observed as a consequence
of T cell dysfunction following PNA therapy for the leukemia [32].
Defective interferon gamma production by mononuclear cells from
patients is thought to underlie the increased risk of facultative organisms
Table 2
Classical and variant hairy cell leukemia can be distinguished on a number of axes with
therapeutic implications.
HCL HCLv
~90% of cases ~10% of cases
Often indolent Often aggressive
Good response to purine
nucleoside analogs
Poor response to purine nucleoside analogs
Good response to biologic
(antibody) therapy
Good response to biologic (antibody) therapy
Usually IGHV mutated Usually IGHV unmutated
Almost always (~90%) BRAFmutant Always BRAF wild-type
IGHV4-34 cases are BRAF wt Often harbor MEK/ERK pathway mutations
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can also be attributed to the intrinsic immune compromise as well as
the severe T cell abnormalities resulting from chemo-immunotherapy
which may be prolonged. Herpes zoster reactivation can be both painful
and dangerous, with a risk of dissemination unless promptly treated.
In patients presentingwith infection at the time of diagnosis, there is
no consensus regarding the best approach to therapy. In the initial
studies utilizing cladribine, patients with fever and active infection
were excluded from the clinical trials [33]. Patients with neutropenia
at the time of initial therapy may have severe and prolonged
myelosuppression in response to cladribine. Therefore, initial therapy
represents the time of greatest risk for the patient in terms of morbidity
and mortality due to infection. Attempts at modiﬁed doses and
schedules of administration of cladribine have not improved on the
safety of using this agent [34,35]. Saven and colleagues explored the
use of ﬁlgrastim, and showed that it reduced the duration of neutropenia
with little impact on infection prevention [36,37].
In contrast, the interrupted schedule of pentostatin administration
has enabled the use of this agent in treating some patients with hairy
cell leukemia in the midst of infection [38]. Alternatively, interferon as
a single agent may lead to improvement in the peripheral blood counts
and has been used to effectively treat patients with infection who
require therapy. The adjunctive use of ﬁlgrastim in this setting may
also facilitate a successful control of infection. If alpha interferon is
used as an initial therapy to improve hematologic parameters and
control infection, the subsequent use of a purine analog can achieve a
more durable complete remission after the patient is stabilized and
the underlying infection is controlled [39,40]. Prior exposure to alpha
interferon does not preclude subsequent response to pentostatin [38].
During induction therapy for HCL and subsequent follow-up, the use
of prophylaxis for P. jirovecii pneumonia (PJP) andherpes simplex virus/
varicella zoster virus (HSV/VZV) is not uniformly practiced. Both
pentostatin and cladribine are known to result in signiﬁcant
lymphodepletion of both B- and T-cells [41], which typically lasts for
manymonths. Similar T cell defects have also been documented in breast
cancer patients following bendamustine [42,43], as this agent has chem-
ical structural features similar to the purine analogs. Consequently, some
investigators in our practice administer prophylaxis for PJP andHSV/VZV
following the use of a purine nucleoside until an empirically derived end-
point of the CD4+ count exceeding 200 is documented [44]. However,
the absolute necessity for this additional prophylaxis therapy has not
been established for patients being treated with a PNA as monotherapy.
Furthermore, patients being treated with more than one agent (e.g.,
combined chemo-immunotherapy) or those receiving multiple cycles
of therapy may be at an increased risk for infection. There is currently
no data to guide the use of prophylactic antibacterial or antifungal
medications and in our practice these are not routinely administered.
The routine use of growth factor support such as ﬁlgrastim is not
supported by available data showing a lack of signiﬁcant clinical beneﬁt
[36], however this agent may be useful in some situations (e.g., as an
adjunct for treating patients with active infection). Clinical research todeﬁne the optimal strategy for managing and preventing the infections
encountered in these patients is clearly needed.
The administration of immunizations has not been studied
speciﬁcally in patients with HCL, however guidelines exist for the
immunization of immunocompromised individuals [45]. The humoral
response to immunization following PNA therapy is unknown but
would be expected to be signiﬁcantly lower than the general
population, as was demonstrated in rheumatoid arthritis patients who
had received prior rituximab [46]. We routinely administer immuniza-
tions to eligible patients including seasonal inﬂuenza immunization,
adult booster immunizations for tetanus andpertussis, andpneumococcal
vaccines every ﬁve years as scheduled. We discourage HCL patients from
receiving live vaccines such as varicella zoster, inﬂuenza nasal mist, or
measles/mumps/rubella, as these could result in acquisition of viral
disease.
One study which evaluated the long-term risk of infection in pa-
tients with HCL found that the increased risk appeared to be conﬁned
to the ﬁrst year following diagnosis, with infection risk approaching
that of the general population subsequent to this [47].
Long-term data with either purine nucleoside analog show that at
least 40% of patients will relapse from the initial hematologic remission
and require further treatment for the leukemia [48]. The occurrence of
chronic bacterial or fungal infection during initial therapy raises serious
difﬁculties for providing subsequent therapy with a purine analog if the
patient should relapse. The long-term improvement in survival as a
result of purine analog therapy paradoxically increases the risk that
these challenging therapeutic questions will be encountered [49].
3.2. Autoimmunity
Patients with hairy cell leukemia can also experience auto-immune
complications associated with their underlying disease [5]. Vasculitis
presenting as leukocytoclastic vasculitis has been associated with
infection. A recurrent inﬂammatory arthropathy similar to rheumatoid
arthritis has been observed [50]. The autoimmune complications may
not improve in parallel with treatment of HCL. Autoimmune red cell
destruction and thrombocytopenia have been rarely reported as well
[51,52]. While these manifestations are likely related to the underlying
disease, there is a concern that autoimmune cytopenias may be aggra-
vated by purine analogs. The underlying biology responsible for these
autoimmune complications represents another area of needed research.
3.3. Second malignancies
The long-standing question related to a possible increase in second
malignancies also implicates an abnormal immune status in these pa-
tients, either as an intrinsic problem emanating from the leukemia or
as a consequence of its treatment [53]. In a large population-based
study, Hisada reported an increased incidence of Hodgkin Lymphoma,
non-Hodgkin Lymphoma, and thyroid cancer [54]. Remarkably, several
patients in our experience have been observed to have both hairy cell
leukemia and malignant melanoma. Considering the role of BRAF
p.V600E mutations in many of these malignancies, a careful epidemio-
logical investigation of the frequency of melanoma and thyroid cancer
should be conducted in patients with this rare form of leukemia [55].
4. Management
Optimal management of patients with this rare form of leukemia
begins with establishing the correct diagnosis and evaluating the
predictive biomarkers for risk stratiﬁcation. The tremendous progress
that has been made in improving the initial responses of patients with
the classic form of this disease has resulted in dramatic improvements
in long-term disease control and survival, but the ultimate progression
free survival curves show no plateau, indicating that the disease is not
cured by current therapies [9–13]. However, prolonged durable
200 M.R. Grever et al. / Blood Reviews 28 (2014) 197–203remissions enable patients to lead highly functional lives. Long-term
follow-up studies now show that patients live for periods approximat-
ing the normal life-span. Therefore, younger patientswith hairy cell leu-
kemia have a higher chance of achieving a complete remission, but an
equally high chance of experiencing several relapses throughout the
course of their lifetime [8]. A recent publication examined the outcomes
of patients under the age of fortywith this disease and showed that they
had a very long life but had multiple relapses requiring therapy [49].
Deﬁnition of prognostic subsets and the recognition that the variant
form of hairy cell leukemia is a distinct clinical entity have improved the
therapeutic plans for patients who are newly diagnosed [13,17–20,23,
24]. Clinical experience has long taught us that even among the classic
form of the disease there are several subsets of patients with distinct
prognostic proﬁles, and this experience has been borne out by recent
molecular discoveries. Patients harboring the biomarkers predictive of
less optimal response may have overlapping immunophenotypic
markers, variable BRAF mutational proﬁles, abnormalities of TP53
genes, or stereotypical immunoglobulin gene rearrangements (e.g.,
IVH4-34) resulting in different clinical outcomes. These biological and
molecular variations will need to be validated as accurate predictors of
long-term outcome [20,21,24–26].
In patients with classic hairy cell leukemia, standard therapy
involves induction with a purine nucleoside analog (Fig. 1). Patients
treated with either pentostatin or cladribine are expected to achieve a
durable complete remission in at least 76–91% of the cases [9,37,48,56].
In those treated with pentostatin, there is a lower reported frequency
of febrile neutropenia [38]. Typically, patients are treated with
pentostatin at twoweek intervals in the outpatient clinic until a complete
remission has been documented [38]. This induction therapy could re-
quire six months or longer to secure a complete response. While many
of these patients are then treated with two additional courses of
pentostatin as consolidation, whether this additional therapy is required
is still unclear. In contrast, patients treatedwith cladribine usually receive
a single ﬁve to seven day course of therapy and are followed until a com-
plete remission has been documented. In those patients achieving a com-
plete response to either therapy, no evidence of residual hairy cell
leukemia can be observedmorphologically. Immunohistochemical stains
on the bone marrow biopsy or immunophenotypic analysis of the bone
marrow aspirate may reveal minimal residual disease (MRD) in these
patients. Another area for a continued discussion entails establishing a
uniformdeﬁnition of a complete remission, and the reproducibility of de-
ﬁning negativeMRD status following therapy. Establishment of a consen-
sus on the deﬁnition of a complete response and the necessity for
quantifying the extent of MRD by various methods including immuno-
histochemistry, ﬂow cytometry, or deep sequencing should be a priority.
While the extent of MRD remaining after initial therapy is generally
felt to be important with respect to predicting long-term outcome, the
quantitative extent and timing of these assessments are important
[32,57,58]. More work is needed in the context of organized clinical
trials to validate these relationships. A consensus in terms of the
importance of eradicating MRD requires a general agreement on the
deﬁnitions of complete remission, thresholds for identifying MRD, and
relapse. While most deﬁnitions of complete remission require that no
morphologic evidence of hairy cell leukemia can be observed on rou-
tine hematoxylin and eosin staining of the bone marrow, many
hematopathologists report the percentage of residual hairy cell inﬁltra-
tion based upon immunohistochemical stains or immunophenotypic
analyses of bone marrow ﬂow cytometric studies. Following purine an-
alog therapy, there can be delayed and continuous improvements in
bone marrow leukemic cell inﬁltration [32]. The assessment of residual
hairy cell leukemic inﬁltration thus may vary depending upon the time
of analysis. Furthermore, there may be sampling errors associated with
studies performed on themarrow aspirate due to the variable degree of
bone marrow ﬁbrosis. In contrast, immunohistochemical stains on the
core biopsy may yield more reproducibility in quantitative determina-
tion of MRD.Administration of combined chemo-immunotherapy in an effort to
totally eradicateMRDmust be based upon an acceptable toxicity proﬁle
and the time frame for this analysis. While many advise waiting several
months before examining the remission bone marrow for evidence of
MRD, a recent study by Ravandi evaluated the bone marrow one
month following therapywith cladribine [59]. The subsequent adminis-
tration of eight weeks of rituximabwas reported to produce a complete
remission in 100% of the patients. It is not clear whether or not some of
these patients would have achieved an MRD-negative bone marrow if
adequate time had elapsed before analysis. Despite caution from the
authors that this combined approach to chemo-immunotherapy should
not be considered standard of care, the published resultsmay be used to
justify the administration of eight weeks of immunotherapy in many
non-protocol circumstances. In addition to the additional cost of the
immunotherapy, there may be added immunosuppression as a result
of this combined chemo-immunotherapy. While this combination of
chemoimmunotherapy has been utilized in patients who relapsed
following an initial purine analog therapy, it is unclear if this combina-
tion is justiﬁed as an actual front-line therapy. Therefore, there is
ample opportunity for continued clinical research to reﬁne our best
therapeutic approach.
Kreitman and colleagues at NCI are investigating whether a pu-
rine analog and immunotherapy with an anti-CD20 antibody are
better administered as combined or sequential therapy. It is un-
clear how many doses of the monoclonal antibody are needed for
an optimal response or even whether or not rituximab is the mono-
clonal antibody of choice. Considering the successes of newer anti-
CD20 monoclonal antibodies (for example, the glycoengineered
anti-CD20 obinutuzumab [60]) in similar diseases like chronic lym-
phocytic leukemia and non-Hodgkin lymphoma, additional
investigation with these agents in HCL is certainly needed. Novel
biologic therapies show great promise and are areas for further
evaluation in the optimization of therapy [61]. The rarity of this
form of leukemia and the tendency for these patients to be treated
in a non-protocol setting confound the investigations. Consequently,
efforts are underway to develop global protocols to address these
questions. Inter-institutional collaboration will be required to answer
such questions in this rare disease (e.g., perhaps through the Hairy
Cell Leukemia Research Foundation). For patients who relapse follow-
ing the standard therapy with classic hairy cell leukemia or for those
rare patients with the variant of this disease, there is an urgent need
to enter patients onto organized clinical trials. Many new and exciting
agents hold promise for these patients.
5. Emerging treatments
For years, immunotoxin conjugates (e.g., HA-22) have been studied
in patients with relapsed disease. In patients with resistant or relapsed
hairy cell leukemia expressing CD22, the immunotoxin conjugate has
been reported to result in complete responses in 46% of patients [62].
Many of these patients have had durable remissions with tolerable
toxicities. The recent observation that patients with classic hairy cell
leukemia carry BRAF p.V600E within their leukemic cells prompted
the exploration of the BRAF inhibitor vemurafenib in the setting of re-
lapsed and resistant disease [63]. In patientswithwell-documented fail-
ures to respond to multiple standard agents, this targeted therapy has
achieved durable remissions [64–66]. Studies in both New York and
Italy are formally exploring this agent in the setting of relapsed
disease. Patients have been reported to show a rapid response to
vemurafenib and other BRAF V600E inhibitors. The optimal therapeutic
regimen with vemurafenib has yet to be deﬁned. Many of the current
studies simply utilize the dose and schedule derived from other trials
in patientswithmetastaticmelanoma. Considering the cutaneous toxic-
ities, there may be other doses and schedules of administration that
would provide better outcomes in hairy cell leukemia. In patients who
have relapsed, a search for pathways of resistance has suggested that
Symptoms No Symptoms
Bone Marrow Failure Watch, Wait, Follow Carefully
Enlarged Spleen
Absolute neutrophils <1,000/µL
Hemoglobin <10 gram/dL If change observed go
Platelet Count < 100,000/µL back to symptoms
Treatment with Purine Nucleoside Analog
Cladribine 
or 
Pentostatin
Documentation of Response
Following pentostatin, bone marrow biopsy after normalization of blood count and 
physical exam
Bone marrow biopsy approximately 4 months after chemotherapy following cladribine
Complete remission requires normalization of peripheral blood count for at least one 
month with no evidence of HCL by morphology in bone marrow and peripheral blood
Define extend minimal residual disease on bone marrow biopsy detectable by 
immunohistochemical stains. 
Decision to add additional therapy for patients not achieving a complete remission and 
document duration of response
Patient Follow-up: 
Quarterly with complete blood counts.
Establish Accurate Diagnosis and Prognosis
Fig. 1. Treatment algorithm for hairy cell leukemia (HCL).
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that the MEK–ERK pathway has both diagnostic and therapeutic target
potentials in hairy cell leukemia [67]. In a recent brief publication, the
clinical efﬁcacy of vemurafenib was associated with BRAF inhibition,
but surprisingly there was an uncoupling with phospho-ERK as mea-
sured in the in vivo leukemic cells obtained from the patient [68].
Thus, this intriguing pathway holds promise for therapeutic interven-
tion while presenting ample opportunity for further investigation of
pharmacodynamic effects.Table 3
Long-term results of treatment: hairy cell leukemia.
Author Year Agent Numbe
Goodman, GR 2003 Cladribine 207
Chadha, P 2005 Cladribine 85
Else, M 2009 Cladribine 45
Pentostatin 188
Flinn, I 2000 Pentostatin 240
154 ﬁr
86 afte
Johnston, J 2000 Pentostatin 28
a CR = mophologic absence of hairy cell in blood and bone marrow and normalization orga
b RFS = relapse free survival measured from time of treatment until relapse.While BRAF inhibitors provide an option for patients with classic
hairy cell leukemia in need of novel therapy, patients with the variant
forms of this disease require other strategies. Patients with hairy cell
leukemia variant do not respond well to standard purine analog treat-
ment with low response rates and less durable remissions. They do
not have BRAFmutations, eliminating both standard therapy as well as
BRAF-targeted therapies. Patients with the variant may respond to
HA-22, and responses have been observed with cladribine in combina-
tion with rituximab [17]. Recently, a multi-institutional trial involvingr of patients CRa % Median duration of CR
95 44 months
79 35 months
76 Overall median RFSb 16 years
82
st line 76 10 year relapse free
r interferon 66 67%
90 56% relapse-free at 119 months
nomegaly and cytopenias.
Table 4
There remain many areas of active or ongoing research as well as many opportunities for new research in hairy cell leukemia.
Areas for further investigation Status
Role of small molecule therapy Clinical trials of ibrutinib and vemurafenib underway.
Role of biological therapy Clinical trials of monoclonal antibodies and antibody-drug conjugates have been very successful in ALL, CLL, and NHL.
These should be extended to HCL to identify the optimal biologic agent(s) for use in this disease.
Minimal residual disease: impact on long term
survival and need for additional or modiﬁed therapy
MRD deﬁnable by ﬂow cytometry, immunohistochemical stains, and deep sequencing; optimal methods for quantitating
MRD require validation; the prognostic impact of MRD is not yet deﬁned and requires prospective evaluation.
Infectious prophylaxis Prophylaxis use is variable; a large retrospective multicenter study could deﬁne its utility.
202 M.R. Grever et al. / Blood Reviews 28 (2014) 197–203the BTK inhibitor ibrutinib has begun to enroll patients with both the
classic form in relapse and the variant of this disease (http://
clinicaltrials.gov/ct2/show/NCT01841723). The necessity to explore
novel therapies with tolerable side effects is highly warranted, as stan-
dard therapy is associated with toxicity and limited duration of
response.
6. Future clinical investigation
The opportunities for clinical investigation in the ﬁeld of hairy
cell leukemia encompass novel targeted therapeutic agents. While
tremendous progress has beenmade in treating this disease, the evidence
shows that we control the leukemia but do not cure these patients.
Because they now live longer, patients face recurrent relapses and can
be confronted with the risk of cumulative immunosuppression as well
as off-target effects of therapy. The formation of an international
organization – Hairy Cell Leukemia Research Foundation – dedicated to
improving the outcome for these patients will enable a long-term
assessment of quality of life issues. Establishment of an international
clinical database will provide the ability to address issues relating to
risks for infection, second malignancies, impact of treatment on fertility,
employability, and other valuable measures, reﬂecting the beneﬁt of
participating in an organized clinical registry of a chronic disease. While
we are pleased with the substantial improvement in outcomes for
patients who have beneﬁtted from effective therapy, we need to
understand and focus on the remaining unresolved issues that warrant
further clinical investigation. Long-term results are presented in Table 3.
Despite considerable progress in understanding this disease, many inter-
esting clinical and epidemiological questions remain. The opportunities
for ongoing and new research in hairy cell leukemia are presented in
Table 4. In fact, the Hairy Cell Leukemia Research Foundation was
established to address these issues in centers of excellence across the
globe (www.hairycellleukemia.org).
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